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Background
Since the introduction of combination antiretroviral therapy (ART), human immunodeficiency virus (HIV) infection has evolved from a generally fatal condition to a manageable chronic disease [1] . In treated people with HIV (PWH), morbidity and mortality have shifted to non-infectious etiologies, and cardiovascular disease (CVD) has become a major concern with an estimated incidence of first cardiovascular or cerebrovascular events of 5.7 per 1000 person-years. The pathophysiology of CVD in PWH is not fully understood but is considered a combination of traditional cardiac risk factors and inflammation [2] driven by cytokines, co-infections such as cytomegalovirus (CMV), monocyte activation and residual viral replication [3] .
Despite improvement in HIV care, many patients are still diagnosed at later stages of disease and are at high risk for immune reconstitution inflammatory syndrome (IRIS) [4] , which occurs in approximately 25% of HIV-patients starting ART at low CD4 counts [5] . IRIS is an aberrant inflammatory condition with new manifestations or deterioration of symptoms consistent with an infectious/inflammatory disease that typically occurs shortly after the initiation of ART. It is characterized by a rise of proinflammatory molecules of both T-cells and myeloid origin [6] . It is unclear though if this inflammatory milieu leads to higher levels of chronic residual inflammation.
The primary aim of this study was to evaluate the residual chronic inflammatory state, with a focus on CVD biomarkers, of PWH who have successfully remained virally suppressed 3 years after ART initiation and to assess the potential contribution of IRIS events in chronic residual inflammation. A secondary objective was to evaluate the potential role of CMV infection with end organ disease (EOD) at therapy initiation and the role of subsequent CMV reactivation on chronic residual inflammation.
Methods

Study design and population
The current study was a post-hoc retrospective analysis from a previously published prospective observational study [7] conducted under an Institution Review Board approved protocol months thereafter. For this study, only US-site enrolled participants were included if they had maintained virologic suppression with a viral load under 500 copies/ml at week 160 study visit (year 3).
Definitions
Suspected IRIS events were adjudicated by a review committee according to the ACTG IRIS definition criteria as previously described [7, 8] . IRIS events were classified as paradoxical or unmasking, and according to the infectious agents involved. CMV related EOD was confirmed either by ophthalmologic examination of retina or by pathologic confirmation for gastrointestinal and pulmonary sites.
Participants were divided into different groups according to the development of IRIS before week 24 study visit and according to development of a CMV EOD during the first 24 weeks following ART initiation or CMV reactivation after week 24 study visit until the end of study (defined as a positive viremia by blood PCR during any of the scheduled study visits between week 24 and week 160).
Measurement of soluble biomarkers
After a literature search, we selected biomarkers associated with inflammation and coagulation, with a focus on biomarkers of interest in CVD [9] [10] [11] [12] . The soluble markers were tested in cryopreserved stored plasma sampled at week 160 study visit, using Electrochemiluminesence (MESO), ELISA and ELFA (bioMerieux ® , Marcy l'Etoile, France) (Supplemental data). The biomarkers were only evaluated at week 160 and we were also able to retrieve values for some of the biomarkers at week 0 because they were included in the main study protocol. We measured biomarkers that are associated . D-dimer, hsCRP and lipid profile were evaluated prospectively at the clinical laboratory. Inflammatory and coagulation biomarkers chosen have been found elevated in various previous studies of IRIS by our group and others [6, 13, 14] .
Statistical analysis
Statistical tests were two-sided, with type I error rate of 5% as an initial threshold, though due to the multiple comparisons being made any p-values between .01 and .05 were treated as suggestive but not definitive. Data are presented as median values with interquartile range (IQR), or as percentages. 
Results
Participants' inclusion and clinical presentation
Among 206 participants prospectively enrolled in the main study, 143 met the substudy defined criteria and were included in this analysis (Supplemental Figure 1 ). The median age at week 160 was 43 (IQR 34; 50) and 72% were male (Table 1 ). Participants' characteristics at baseline are presented in Table 1 and in Supplemental Table 1 . At baseline, 68 (47.6%) of the participants were diagnosed with 80 opportunistic infections. In agreement with previous epidemiologic studies in the US [15] , the most common infections were Pneumocystis jirovecii pneumonia (25 events, 35%) and mycobacterial infections (16 events, 23%) (Supplemental Table 1 ). No cardiovascular events were reported in the cohort during follow-up up to 3 years.
IRIS events
There were 43 IRIS events that occurred in 39 individual participants; 15 (35%) paradoxical and 28 (65%) unmasking. As previously described [1, 7] , the most common IRIS events were related to bacteria (either Mycobacterium avium Complex (MAC) (11 events, 26%) or Tuberculosis (7 events, 16%)) (Supplemental Table 2 ). In accordance with previous studies [16] , participants who developed IRIS had higher plasma HIV viremia, plasma CRP levels, and lower CD4 and CD8 T-cell counts at baseline than those who did not develop IRIS (Supplemental Table 1 ). ART regimens were not different between the two groups (Supplemental Table 3 ).
Of the 143 subjects, 13% had a CMV EOD before week 24 and 10% presented with CMV viremia between week 24 and the end of the study (Table 1) , with no differences in participants' characteristics at baseline (Supplemental Table 4 ).
Biomarker evaluation
At week 160, there were no statistically significant differences in the levels of any of the tested biomarkers based on IRIS development (Table 2) , CMV viremia (Supplemental Table 5 ) or CMV EOD during the first 24 weeks following ART initiation (Supplemental Table 6 ). There were also no differences according to IRIS subtype. In a logistic regression model adjusting for all significant biomarkers (hsCRP, IFNγ, TNF-α, IL6, IL15, IL17α, IL18, IL21, sCD14, Homocysteine), we found that only low IL15 and low homocysteine at week 160 study visit were slightly associated with a previous IRIS event (p=0.03 and p=0.02 respectively) (Supplemental Table 7 ).
Discussion
IRIS is considered the result of an imbalanced recovery between innate and adaptive immune responses after ART initiation, leading to a hyperactivation of T cells, mostly Th1 and Th17. Despite significant research on IRIS pathogenesis and short-term outcomes, the long-term consequences of this acute inflammatory condition are unknown. To our knowledge, this is the first study to evaluate the late inflammatory state of IRIS participants followed prospectively by measuring an extensive panel of 39 biomarkers 3 years after ART initiation in PWH with controlled viremia, and found no differences in the inflammatory state of participants who had experienced IRIS compared to those who did not.
Inflammation is an important contributor to the development of CVD [9] . At the early stages of atherogenesis, activation of endothelial cells occurs in response to injurious factors (such as dyslipidemia or hypertension) and inflammatory mediators [9] , with involvement of both innate and adaptive immunity signals [9] . HIV-infected individuals who develop IRIS are known to have an increased inflammatory state at baseline [6] and a dramatic rise in pro-inflammatory biomarkers during the IRIS event. One could speculate that such a pro-inflammatory milieu may persist and lead to higher chronic inflammation and eventually to a higher incidence of CVD events. In contrast to our hypothesis though, in this cohort of participants with low baseline CD4 counts, we were unable to find major differences in inflammation, as measured by biomarkers in systemic circulation, of PWH based on history of IRIS.
IRIS mortality is estimated to be 4-5%, usually occurring in the first 6 months following ART initiation, although this is likely under-estimated as the relation between death and the IRIS event can be hard to ascertain [17] . We could hypothesize that the absence of major differences in our study might be related to the early death of the participants that displayed the higher inflammatory cytokine storm. However, the mortality rate in this cohort was very low and only one participant with IRIS died. It is also possible that by excluding people who had a high viral load after three years, there was insufficient power to detect differences. Alternatively, it is plausible that corticosteroids prescribed for IRIS treatment might have successfully and definitively counter-balanced the excess inflammation.
Our secondary aim was related to CMV end organ disease and viremia given the reported association of CMV with CVD [18] . CMV infection induces the expression of pro-inflammatory mediators and proangiogenic factors by endothelial cells, promoting monocyte migration in the vascular wall, thus contributing to atherosclerosis. Asymptomatic CMV replication, which occurs mostly in various mucosal sites and effector tissues, has been linked to higher immune activation and HIV disease progression [18] . Because CMV replication is enhanced by inflammatory stimuli and in turn increases inflammation, the vicious cycle of CMV and inflammation is hard to decipher, especially in HIV-related chronic inflammation. Some studies have suggested that CMV replication may promote inflammation in compartmentalized effector tissues [19] , which could explain the absence of relationship between inflammatory biomarkers and CMV replication in our study.
If we focus on the IRIS analysis, with group sizes of 38 and 122, respectively, this study would have 80% power to detect a mean difference of about 0.5 standard deviations. For TNFa expression, for example, we are 95% confident that the difference between the group means is between -30% to 2%; this suggests that we have ruled out a large difference between the groups, but not necessarily modest differences. Similarly, though there is a little more variability for other important covariates such as IL6
and IFNγ, we are confident that if there were any difference between the groups the magnitude of the difference would be lower than about .4 to .7 log, respectively.
Our study has additional limitations. First, our list of immune biomarkers was not exhaustive and there might be more relevant than those investigated, however, we evaluated markers that were most informative based on a thorough literature review. Second, the absence of a non-HIV infected participant cohort did not allow us to assess if the PWH included had a persistent chronic inflammatory state, but this has been well established in several previous studies [20] . Third, follow-up was limited to 3 years without non-AIDS-related events in the cohort. It is conceivable that longer follow-up of a larger cohort would have shown differences. Finally, we only sampled peripheral blood and local inflammation at the tissue level could not be assessed.
Despite these limitations, our study represents the largest cohort so far to compare late inflammatory status among PWH according to a previous IRIS event. We believe the complete lack of differences suggests that at least at the peripheral blood level, a large impact is unlikely. Clinical follow-up of those participants will be interesting to determine the incidence of clinical CVD in the future. 
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